Table 1

Genotype and haplotype frequencies of CYP3A4 and CYP3A5 variants in prostate cancer cases and sibling controlsa

Genotype/HaplotypeAllelesAll SubjectsbCaucasiansAfrican-Americans
CasesControlsCasesControlsCasesControls
CYP3A4 c
*1A/*1A376 (87%)402 (86%)362 (93%)391 (92%)11 (29%)8 (21%)
*1A/*1B39 (9%)52 (11%)24 (6%)34 (8%)13 (34%)16 (42%)
*1B/*1B18 (4%)15 (3%)4 (1%)1 (0.2%)14 (37%)14 (37%)
CYP3A5 c
*3/*3345 (78%)366 (76%)337 (85%)359 (82%)6 (16%)5 (13%)
*3/*178 (18%)94 (20%)57 (14%)75 (17%)18 (47%)16 (42%)
*1/*117 (4%)20 (4%)3 (0.8%)3 (0.7%)14 (37%)17 (45%)
CYP3A4/CYP3A5 d
*1A/*3738 (85%)798 (85%)710 (91%)769 (90%)21 (28%)22 (29%)
*1A/*153 (6%)58 (6%)38 (5%)47 (6%)14 (18%)10 (13%)
*1B/*158 (7%)73 (8%)24 (3%)31 (4%)32 (42%)40 (53%)
*1B/*317 (2%)9 (1%)8 (1%)5 (0.6%)9 (12%)4 (5%)
  • a Frequencies are calculated from the total number of samples successfully genotyped for each variant.

  • b All subjects include 8 Hispanics (4 cases and 4 controls) and 2 Asian-Americans (1 cases and 1 control).

  • c Counts are for the number of individuals.

  • d Counts are for the number of haplotypes.